475 related articles for article (PubMed ID: 25496335)
1. Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.
Ballesteros-Tato A
Immunotherapy; 2014; 6(11):1207-20. PubMed ID: 25496335
[TBL] [Abstract][Full Text] [Related]
2. The Potential of Harnessing IL-2-Mediated Immunosuppression to Prevent Pathogenic B Cell Responses.
Papillion A; Ballesteros-Tato A
Front Immunol; 2021; 12():667342. PubMed ID: 33986755
[TBL] [Abstract][Full Text] [Related]
3. Biological effects of IL-21 on different immune cells and its role in autoimmune diseases.
Gharibi T; Majidi J; Kazemi T; Dehghanzadeh R; Motallebnezhad M; Babaloo Z
Immunobiology; 2016 Feb; 221(2):357-67. PubMed ID: 26466984
[TBL] [Abstract][Full Text] [Related]
4. Fine tuning subsets of CD4
Zhao Z; Zhang X; Su L; Xu L; Zheng Y; Sun J
Int Immunopharmacol; 2018 Mar; 56():269-276. PubMed ID: 29414661
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1 in the Response of Follicular Helper and Follicular Regulatory T Cells.
Ritvo PG; Klatzmann D
Front Immunol; 2019; 10():250. PubMed ID: 30873158
[TBL] [Abstract][Full Text] [Related]
6. The effector T helper cell triade.
Fietta P; Delsante G
Riv Biol; 2009; 102(1):61-74. PubMed ID: 19718623
[TBL] [Abstract][Full Text] [Related]
7. Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity.
Kosmaczewska A
Int J Mol Sci; 2014 Oct; 15(10):18574-92. PubMed ID: 25322151
[TBL] [Abstract][Full Text] [Related]
8. Low-dose IL-2 therapy in autoimmune diseases: An update review.
Zhang R; Zhao Y; Chen X; Zhuang Z; Li X; Shen E
Int Rev Immunol; 2024 May; 43(3):113-137. PubMed ID: 37882232
[TBL] [Abstract][Full Text] [Related]
9. T-cell-based immunotherapy of autoimmune diseases.
Ulivieri C; Baldari CT
Expert Rev Vaccines; 2013 Mar; 12(3):297-310. PubMed ID: 23496669
[TBL] [Abstract][Full Text] [Related]
10. T helper cells plasticity in inflammation.
Cosmi L; Maggi L; Santarlasci V; Liotta F; Annunziato F
Cytometry A; 2014 Jan; 85(1):36-42. PubMed ID: 24009159
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 and autoimmune disease occurrence and therapy.
Geng X; Zhang R; Yang G; Jiang W; Xu C
Eur Rev Med Pharmacol Sci; 2012 Oct; 16(11):1462-7. PubMed ID: 23111957
[TBL] [Abstract][Full Text] [Related]
12. Precocious Interleukin 21 Expression in Naive Mice Identifies a Natural Helper Cell Population in Autoimmune Disease.
Marnik EA; Wang X; Sproule TJ; Park G; Christianson GJ; Lane-Reticker SK; Jain S; Duffy T; Wang H; Carter GW; Morse HC; Roopenian DC
Cell Rep; 2017 Oct; 21(1):208-221. PubMed ID: 28978474
[TBL] [Abstract][Full Text] [Related]
13. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis.
Hirota K; Hashimoto M; Yoshitomi H; Tanaka S; Nomura T; Yamaguchi T; Iwakura Y; Sakaguchi N; Sakaguchi S
J Exp Med; 2007 Jan; 204(1):41-7. PubMed ID: 17227914
[TBL] [Abstract][Full Text] [Related]
14. Di-(2-ethylhexyl) phthalate adjuvantly induces imbalanced humoral immunity in ovalbumin-sensitized BALB/c mice ascribing to T follicular helper cells hyperfunction.
Han Y; Wang X; Chen G; Xu G; Liu X; Zhu W; Hu P; Zhang Y; Zhu C; Miao J
Toxicology; 2014 Oct; 324():88-97. PubMed ID: 25093321
[TBL] [Abstract][Full Text] [Related]
15. Biology and regulation of IL-2: from molecular mechanisms to human therapy.
Spolski R; Li P; Leonard WJ
Nat Rev Immunol; 2018 Oct; 18(10):648-659. PubMed ID: 30089912
[TBL] [Abstract][Full Text] [Related]
16. Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.
Skrombolas D; Frelinger JG
Expert Rev Clin Immunol; 2014 Feb; 10(2):207-17. PubMed ID: 24410537
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases.
Graßhoff H; Comdühr S; Monne LR; Müller A; Lamprecht P; Riemekasten G; Humrich JY
Front Immunol; 2021; 12():648408. PubMed ID: 33868284
[TBL] [Abstract][Full Text] [Related]
18. Low-Dose IL-2 Induces Regulatory T Cell-Mediated Control of Experimental Food Allergy.
Bonnet B; Vigneron J; Levacher B; Vazquez T; Pitoiset F; Brimaud F; Churlaud G; Klatzmann D; Bellier B
J Immunol; 2016 Jul; 197(1):188-98. PubMed ID: 27259854
[TBL] [Abstract][Full Text] [Related]
19. Sublingual 'oral tolerance' induction with antigen conjugated to cholera toxin B subunit generates regulatory T cells that induce apoptosis and depletion of effector T cells.
Sun JB; Czerkinsky C; Holmgren J
Scand J Immunol; 2007; 66(2-3):278-86. PubMed ID: 17635805
[TBL] [Abstract][Full Text] [Related]
20. Inflammation and lymphopenia trigger autoimmunity by suppression of IL-2-controlled regulatory T cell and increase of IL-21-mediated effector T cell expansion.
Chevalier N; Thorburn AN; Macia L; Tan J; Juglair L; Yagita H; Yu D; Hansbro PM; Mackay CR
J Immunol; 2014 Nov; 193(10):4845-58. PubMed ID: 25339665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
